69 results about "Bone resorption" patented technology

The invention discloses injectable double-drug delivery hydrogel and a preparation method thereof, and belongs to the technical field of biomedical materials. According to the method, two nano microspheres with different charges are respectively prepared by utilizing the characteristics of A-type gelatin and B-type gelatin, a negatively charged medicine EGCG is specifically carried by the positively charged A-type gelatin, and a positively charged medicine SAG is carried by the negatively charged B-type gelatin microsphere; and finally, mixing the two gelatin drug-loaded microspheres into a material taking gelatin and zirconium ions as a substrate to form the composite hydrogel. The hydrogel realizes immune regulation and osteogenesis regulation, also realizes long-acting release of the two drugs, effectively solves the problems of bone resorption, difficulty in healing and the like of host tissues through synergistic regulation of inflammation and mobilization of osteogenesis genes, realizes personalized treatment, and improves the clinical treatment effect and efficiency.

The invention relates to the technical field of oral cavities, and discloses an alveolar bone resorption degree detection method, device and equipment and a medium, oral cavity image data of a patient is obtained, and tooth jaw segmentation data extraction is performed on the oral cavity image data to obtain tooth jaw segmentation data; performing three-dimensional space morphological feature analysis on tooth segmentation data in the tooth jaw segmentation data to obtain tooth coordinate azimuth information; calculating periodontal measurement surface information according to the tooth coordinate azimuth information; extracting enamel boundary line data and alveolar bone boundary line data in the dental jaw segmentation data; calculating an alveolar bone resorption degree result according to the enamel boundary line data, the alveolar bone boundary line data and the periodontal measurement surface information; the alveolar bone resorption degree result is calculated through the boundary line data and the measurement surface information, and the accuracy of the result is improved while the resorption degree is accurately quantified.

The invention relates to the technical field of biomedicine, and particularly provides a mouse model capable of being inductively combined with epithelial cell specific ablation and application of the mouse model. The method comprises the following steps: inserting a '3xFLAG-P2A-CreERT2 'functional frame at a fixed point at a termination codon of a mouse Odam gene, so as to obtain an OdamCreERT2 mouse. The expression specificity of the Odam gene in binding epithelium is verified by a mouse obtained by copulating with a ROSA26mT / mG reporter gene mouse; mice obtained by mating with ROSA26DTA cell ablation mice reveal the indispensable function of binding epithelium in maintaining periodontal barrier and preventing bone resorption. The model retains endogenous Odam expression and functions, supports protein dynamic tracing and space-time specific gene manipulation, and is suitable for researching the effect of binding epithelium in periodontal barrier integrity and alveolar bone resorption prevention.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The invention discloses a method for preparing a phosphorylated salmon collagen peptide-calcium chelate by taking salmon collagen peptide as a raw material, preparing high-calcium binding active peptide (P-CP) through phosphorylation modification and chelating the high-calcium binding active peptide with calcium ions. The method comprises the following steps: (1) enzymolysis preparation of salmon bone collagen; (2) phosphorylation modification of a peptide fragment mediated by sodium tripolyphosphate; and (3) optimizing a calcium ion chelation process. The chelating rate of the obtained P-CP-Ca calcium reaches 91.21%, and structural characterization proves that a phosphate group (PO4 < 2->) is combined with calcium ions through ionic bonds. Animal experiments show that P-CP-Ca can significantly improve the serum calcium level of a calcium-deficiency mouse (the H group recovers to a normal range), reduce the activity of a bone resorption marker TRAP (Target Related Amplified Protein) (which is 25.4% lower than that of a model group), and improve the bone trabecula microstructure (the bone mineral density is improved by 32.7%). The invention provides a new technology for valuable utilization of fishery by-products and development of functional calcium supplements.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

This invention provides an interbody fusion device and its preparation method, comprising: metal endplates symmetrically arranged vertically, with a mesh structure on the surface of the metal endplates, the mesh structure including: a bone mesh on the outer surface of the metal endplates, a coupling mesh on the inner surface of the metal endplates, a metal separator layer fixedly disposed between the bone mesh and the coupling mesh, and a linkage locking seat disposed on the inner surface of the metal endplates; a cable passing through the linkage locking seat on the inner surface of the aforementioned metal endplates; a polymer matrix fixed between the aforementioned pair of metal endplates by the aforementioned shear-resistant structure; a bone graft cavity, which is a cavity jointly formed by the metal endplates and the polymer matrix; and a positioning hole penetrating the aforementioned polymer matrix. This application addresses the technical problems that, with prolonged implantation time, complications such as displacement, coating peeling, settlement, stress shielding, bone resorption in adjacent areas, and delayed inflammatory reactions often occur.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for strengthening bones and tendons and improving osteoporosis and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw material medicines in parts by weight: 25 to 30 parts of bovine bone, 15 to 20 parts of penis cervi, 10 to 15 parts of fructus mali, 8 to 12 parts of fructus corni, 8 to 10 parts of radix angelicae sinensis, 8 to 12 parts of semen sojae germinatum, 8 to 10 parts of rhizoma dioscoreae, 5 to 10 parts of rhizoma polygonati and 5 to 10 parts of liquorice root. In the formula, bovine bone and penis et testis cervi are taken as monarch drugs, malaytea scallop fruit, dogwood and angelica sinensis are taken as ministerial drugs, semen sojae germinatum, Chinese yam and rhizoma polygonati are taken as adjuvant drugs, and liquorice is taken as a conductant drug. All the components of the traditional Chinese medicine preparation have a synergistic effect, and the purpose of treating osteoporosis is achieved by adjusting the levels of ALP, OC and TRACP-5b, improving bone metabolism, increasing bone mineral density and inhibiting bone resorption.

The present application belongs to the field of medicine, and particularly relates to a new target point NCSTN for regulating bone metabolism and application of an agonist of the target point in preparation of a medicine for preventing or treating osteoporosis. One object of the present application is to provide a new target point NCSTN for regulating bone metabolism and application of the target point in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. The present application first discovers a mechanism of treating osteoporosis by using an agonist of NCSTN, and has the effect of inhibiting mature differentiation of osteoclasts and promoting bone formation function of osteoblasts. This is very different from the previously reported mechanism of single inhibition of bone resorption or single promotion of bone formation, and the treatment of osteoporosis by simultaneously acting on bone resorption and bone formation can greatly reduce adverse reactions of the body to the medicine.

This invention discloses an osteoporosis biomarker circRNA and its applications, belonging to the field of biotechnology. This invention demonstrates that circBBS9 and its human homologs are expressed at elevated levels in osteoporosis. Simultaneously, a siRNA capable of knocking down circBBS9 expression was designed. This invention demonstrates that miR-423-3p is a downstream target of circBBS9. circBBS9 expression rapidly increases during osteoclast multinucleation, and inhibiting circBBS9 does not affect the differentiation of osteoclast mononuclear precursors, but weakens osteoclast multinucleation levels and bone resorption capacity, increasing bone mineral density in osteoporotic mice. This proves that the siRNA prepared in this invention can be used as a drug for the prevention and treatment of osteoporosis.

This invention discloses a benzylindole compound, its preparation method, and its application, relating to the field of pharmaceutical technology. The compound, as shown in formula (A), (B), or (C), or its prodrug, deuterated derivative, or pharmaceutically usable salt, is obtained by introducing different substituents at specific positions on the benzylindole core. This type of compound exhibits good catepsin K inhibitory activity and can effectively inhibit osteoclast bone resorption. The preparation method of this invention uses conventional chemical raw materials as starting materials and obtains the target compound through stepwise reactions such as condensation, cyclization, substitution, or acylation. Different types of compounds can share key intermediates. The synthetic route is scientifically designed, the reaction conditions are mild, the catalytic efficiency is high, and the product purification is simple, making it suitable for industrial-scale production.

The application discloses a preparation method of a 3D printing hip joint stress relief heat treatment double-gradient bone support, and the method comprises the following steps: acquiring image data by performing three-dimensional scanning on a bone defect by means of a CT scanning device, designing the size and shape of a transplantable bone, designing a concave hexagonal support structure with gradient porosity by means of UG three-dimensional drawing software, and gradually transitioning from a Ti-35Nb-5Ta-7Zr alloy with good biocompatibility and a low elastic modulus to a Co-Cr-Mo alloy with good wear resistance and corrosion resistance, improving metallurgical incompatibility, obtaining better interface combination, minimizing bone resorption and aseptic loosening caused by wear, prolonging the service life of an implant, and performing annealing heat treatment on the functional support after printing to eliminate residual stress and depositing a HA coating to enhance cell activity.

The application belongs to the field of treating blood vessel-bone coupling imbalance diseases in traditional Chinese medicine, and particularly relates to a composition for treating blood vessel-bone coupling imbalance diseases, a pharmaceutical preparation and application. Geniposide alone or in combination with crocin I can effectively reduce endothelial cell damage under pathological stimulation conditions, reduce the level of cell apoptosis and the degree of oxidative stress, improve the vascular endothelial function state, and can also significantly inhibit osteoclast differentiation, reduce the number of mature osteoclasts, and reduce bone resorption activity, thereby being conducive to restoring the dynamic balance between bone formation and bone resorption.

The invention discloses application of Crlf2 in preparation of a medicine for preventing, relieving and / or treating osteoporosis, and relates to the technical field of new application of medicines. According to the application of the Crlf2 in preparation of the medicine for preventing, relieving and / or treating the osteoporosis, the key regulation and control function of the Crlf2 in differentiation of bone tissue related cells and osteoporosis diseases is disclosed for the first time, and a new theoretical perspective is provided for pathogenesis of the osteoporosis; it is found that the Crlf 2 inhibitor (such as a specific antibody or a small molecule inhibitor) can be directly used for preparing the efficient and high-targeting anti-osteoporosis medicine, the limitation of existing treatment means (such as bisphosphonate medicine inhibiting bone resorption but not promoting bone formation) is broken through, and accurate intervention aiming at a specific signal channel is achieved.

The invention provides application of xylotetraose or a composition of xylotetraose and nystose in preparation of an anti-osteoporosis product. The invention discloses the synergistic effect of the xylotetraose and the nystose in the aspect of osteoporosis resistance for the first time. When the zebrafish bone mineral composition and the zebrafish bone mineral composition are combined for use, the bone mineralization degree of zebrafish can be remarkably enhanced, the mineralization rate is increased, osteoblast activity is improved, bone metabolic disorder is effectively reversed, and the synergistic anti-osteoporosis potential of the zebrafish bone mineral composition is fully proved. Meanwhile, the invention also discloses the anti-osteoporosis effect of the xylotetraose for the first time, and the xylotetraose can promote bone mineralization, promote bone formation, inhibit bone resorption and regulate bone metabolism balance to a certain extent.

The invention discloses application of quercidic acid in preparation of a medicine or a medicine composition for preventing or treating diseases or symptoms related to excessive glucocorticoid. According to the application disclosed by the invention, the protective effect of the quercidic acid on the GIONFH is verified through a preclinical model, and evidence that the quercidic acid can be applied to prevention or treatment of the GIONFH is provided. Animal experiments prove that the quercidic acid can inhibit methylprednisolone-induced rat GIONFH, and the action mechanism is related to inhibition of osteoclasts. The medicine or the medicine composition described by the invention can obviously improve the formation of necrotic fossa in femoral head of GIONFH, bone loss of bone trabecula, CTSK positive cell expression, osteoclast formation, bone resorption protein expression and osteoclast overactivity at a lower dosage, and provides a potential prevention and treatment scheme for treatment of GIONFH.

Provided in the present application are a tooth segmentation method and apparatus, a method and apparatus for determining the degree of alveolar bone resorption, and a device and a medium. The tooth segmentation method comprises: on the basis of morphological information of each tooth in a panoramic dental image, determining a tooth morphological map; performing tooth localization on the tooth morphological map; on the basis of an initial position of each tooth in the tooth morphological map, acquiring a region of interest of each tooth from the panoramic dental image; and segmenting the region of interest, so as to obtain a segmentation result of each tooth. The method for determining the degree of alveolar bone resorption comprises: inputting a panoramic dental image into a segmentation model, and determining a tooth contour curve, a first contour line and a second line, wherein the first contour line is a contour line that comprises coronal parts of at least two teeth, and the second contour line is a contour line of alveolar bones of the maxilla and mandible; and on the basis of distribution regions of the first contour line and the second contour line within the tooth contour curve, determining the degree of alveolar bone resorption of the teeth.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus zeae strain and an application thereof, and the preservation number of the lactobacillus zeae strain is CGMCC (China General Microbiological Culture Collection Center) NO.26771. The lactobacillus zeae strain has the advantages that the lactobacillus zeae strain can be used for preparing a lactobacillus zeae strain; the lactobacillus zeae provided by the invention has the effects of inhibiting the activity of pathogenic bacteria, reducing inflammatory factors, inhibiting alveolar bone resorption and regulating digestive tract flora.

This invention discloses the application of an inhibitor of transcription factor C / EBPβ in the preparation of a drug for treating postmenopausal osteoporosis. This invention also discloses the application of transcription factor C / EBPβ in screening drugs that reduce postmenopausal FSH levels, wherein the drugs inhibit the expression of transcription factor C / EBPβ. Furthermore, this invention discloses the application of compounds #11a and CF3CN in the preparation of a drug for treating postmenopausal osteoporosis. This invention reveals for the first time that the C / EBPβ-AEP pathway participates in promoting FSHβ synthesis in a menopausal model. By reducing the transcription factor activity of C / EBPβ, it can reduce FSH expression at the pituitary gland, promote osteogenic differentiation, inhibit osteoclast resorption, and effectively alleviate PMOP symptoms. Compounds #11a and CF3CN can effectively achieve both anti-bone resorption and bone formation-promoting functions, achieving coupled treatment of PMOP.

The invention discloses a 2, 4, 6-trisubstituted pyrimidine compound as well as a preparation method, a pharmaceutical composition and application thereof. The structure of the compound is shown in a formula (I), and the derivative of the compound comprises pharmaceutically acceptable salt of the compound. The compound and the pharmaceutical composition thereof can effectively inhibit the activity level of RANKL in osteoclast precursor cells by regulating and controlling an OPG-RANKL-RANK signal channel (the signal channel is one of key channels for converting the osteoclast precursor cells into osteoclasts), so that bone resorption is inhibited. The 2, 4, 6-trisubstituted pyrimidine compound or the pharmaceutically acceptable salt thereof disclosed by the invention is expected to play a role in preventing and treating bone metabolic diseases, and has an important treatment value for patients with bone metabolic diseases.

The application provides a tumor bone metastasis prediction system and method based on bone metastasis specific bone markers, relates to the technical field of machine learning, and comprises the following steps: an index acquisition module is used for acquiring a plurality of bone marker indexes related to bone metastasis in patient serum obtained by serum detection of a patient; and a bone metastasis prediction module is connected to the index acquisition module, used for inputting each bone marker index into a tumor bone metastasis prediction model trained in advance, so as to predict the early bone metastasis incidence of the patient, thereby providing a reference for clinical diagnosis by doctors. The beneficial effect is that the bone marker content of calcium and phosphorus metabolism regulation indexes, bone formation and bone resorption markers, bone metabolism related hormones and cytokines, and electrolytes in serum is quantitatively detected, and the early bone metastasis incidence is predicted through machine learning, so that the method can be used for early auxiliary diagnosis of tumor bone metastasis, auxiliary evaluation of curative effect in a treatment process and monitoring of metastasis recurrence after treatment, and the detection result can be earlier than clinical symptoms.

The invention discloses an MXene-PEI (at) DMMA-METTL3 / 14 two-dimensional nano composite material as well as a preparation method and application thereof, and belongs to the technical field of biological medicine, MXene is taken as a substrate material, is modified by cationic polymer polyethyleneimine and then is taken as a matrix, is loaded with an METTL3 / 14 complex and is modified with 2, 3-dimethyl maleic anhydride, and the MXene-PEI (at) DMMA-METTL3 / 14 two-dimensional nano composite material is prepared. The preparation method comprises the following steps: preparing MXene powder into MXene dispersion liquid; adding a cationic polymer polyethyleneimine into the MXene dispersion liquid, carrying out a full reaction, carrying out centrifugal washing, collecting the precipitate, and drying to obtain MP compound powder; the preparation method comprises the following steps: preparing an MP dispersion liquid, adding a premixed solution of an METTL3 / 14 complex and 2, 3-dimethyl maleic anhydride into the MP dispersion liquid, and keeping the pH value at 8-9; and after the reaction is completed, centrifugally washing, collecting the precipitate and drying to obtain a final product. Under pH response, METTL3 / 14 is slowly released, the capability of efficiently removing ROS and cfDNA is exerted, and compared with MXene, the METTL3 / 14 slow-release antibacterial agent has higher antibacterial capability; the MXene-PEI (at) DMMA-METTL3 / 14 can also relieve oxidative stress injury caused by ROS (reactive oxygen species) and cfDNA (cell-free deoxyribonucleic acid), and can relieve bone resorption while inhibiting inflammation.

Provided are compositions comprising the HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or proteins comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Provided are methods of osteogenesis, including, for example, enhancing bone repair, macrophage polarizations that regulate pro-inflammatory and anti-inflammatory activities, and bone resorption by osteoclasts and methods of treating inflammatory diseases, spinal cord injuries, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases or enhancing wound healing.

The utility model discloses a double planting universal guide plate which comprises a plate body, the plate body is S-shaped, guide plate parts are arranged at two ends of the plate body, one surface of each guide plate part is a drilling-in surface, the other surface of each guide plate part is a drilling-out surface, the drilling-out surfaces of the guide plate parts at the two ends are arranged on two surfaces of the plate body, and a pair of planting guide holes is formed in each guide plate part. And each pair of planting guide holes are arranged in an inclined cohesion manner, and cohesion is performed from the drilling-in hole surface to the drilling-out hole surface. The guide plate parts are arranged at the two ends of the plate body, can be used for implanting teeth on the left side and the right side correspondingly, can be used for implanting teeth at different side positions, and is flexible to use; according to the implant, the implant guide holes are arranged in pairs, and the two paired implant guide holes are obliquely cohesive, so that a relatively good drilling inclination can be stably obtained, the implant is obliquely implanted, tooth root bifurcation of a real tooth body can be simulated, stress dispersion is facilitated, occlusal stress dispersion is achieved, edge bone resorption is reduced, and the stress performance of the implant tooth is improved.

This invention discloses a traditional Chinese medicine mouthwash, its preparation method, and its application, relating to the field of traditional Chinese medicine technology. The mouthwash is prepared from the following raw materials in parts by weight: 8-20 parts Rehmannia glutinosa, 8-15 parts Lonicera japonica, 6-15 parts Scutellaria baicalensis, 5-8 parts Coptis chinensis, 10-20 parts Forsythia suspensa, 10-25 parts Gypsum fibrosum, 5-10 parts Mentha haplocalyx, 3-6 parts Stevia repens, 4-8 parts honey, and 10-20 parts Crataegus pinnatifida. It has the effects of clearing heat and detoxifying, relieving pain and stopping bleeding, is non-irritating, does not produce drug resistance, and has no toxic side effects on the human body. It has anti-inflammatory and antibacterial effects, while preventing the occurrence and development of oral diseases. It utilizes the basic thinking of traditional Chinese medicine to apply the compatibility of natural herbs, and the raw materials are abundant, readily available, low in cost, and the preparation method is simple, suitable for industrial production. It has a significant and definite therapeutic effect on gingival redness, swelling, bleeding, purulent discharge, alveolar bone resorption, and loose teeth caused by kidney yin deficiency and excessive stomach fire.

The present application belongs to the technical field of cosmetics or drugs, and particularly relates to a composition for treating gingivitis and application thereof. The composition is composed of shikonin acid and shikonin naphthoquinone, and the mass ratio of the shikonin acid to the shikonin naphthoquinone is 10-100:1. The present application has excellent effects in improving gingival bleeding and inhibiting alveolar bone absorption. The shikonin acid is prepared by high-pressure steam explosion combined with ethanol extraction, activated carbon decolorization and macroporous adsorption resin technology, and the shikonin naphthoquinone is prepared by supercritical CO2 extraction combined with molecular distillation technology. The preparation method is green, stable and controllable, the obtained active ingredient has high purity, and is suitable for industrial production. The composition of the present application is derived from natural plant ingredients, has high safety, can be prepared into various oral care dosage forms such as gels, toothpastes and mouthwashes, is used for the auxiliary treatment or daily care of gingivitis, and has good application prospect.

The invention provides a polypeptide medicine for treating osteoporosis and a preparation method of the polypeptide medicine, and belongs to the technical field of biological medicine, and the polypeptide medicine comprises the following components: Pleurotus niger peptide, soybean meal protein peptide, a Chinese sumac leaf-broussonetia papyrifera leaf extract, a ulmus pumila leaf-Sophora japonica leaf extract and the like. The method comprises the following steps: sequentially fermenting Pleurotus tuber-regium through candida utilis and lactobacillus plantarum, carrying out enzymolysis through ficin protease, and purifying through a G-50 sephadex column to obtain the Pleurotus tuber-regium peptide. The soybean meal protein peptide is prepared by sequentially carrying out enzymolysis on soybean meal through cellulase, trypsin and bromelain and purifying through an LH-60 sephadex column. The Chinese sumac leaves and the paper mulberry leaves are extracted through an ethanol aqueous solution and purified through a DEAE cellulose column, and the Chinese sumac leaf-paper mulberry leaf extract is prepared. The ulmus pumila leaves and the sophora japonica leaves are sequentially subjected to enzymolysis through cellulase, pepsin and ficin, and purification is conducted through a 732 cation exchange resin column to prepare the ulmus pumila leaf-sophora japonica leaf extract. The components are compounded, so that the bone resorption process is blocked, bone formation and mineralization are strengthened, and osteoporosis is improved.

The invention discloses a peptide YIYT with osteoporosis relieving and antioxidant activity as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the lactoferrin hydrophobic peptide YIYT is tyrosine-isoleucine-tyrosine-threonine (Tyr-Ile-Tyr-Thr, YIYT), and the lactoferrin hydrophobic peptide YIYT has a structural formula shown in the description. Experiments prove that YIYT can significantly promote proliferation, differentiation and mineralization of osteoblasts, accelerate the cell cycle process, inhibit osteoclast activity, reduce bone resorption level and recover bone metabolic balance. In an animal model, the YIYT can effectively improve the bone density of ovariectomized mice and improve a bone-related microstructure, and has double effects of promoting bone formation and inhibiting bone resorption. The lactoferrin hydrophobic peptide YIYT provided by the invention is safe in source and clear in action mechanism, and provides a new candidate substance and an application direction for developing a novel anti-osteoporosis medicine.

The invention provides traditional Chinese medicine granules for improving osteoporosis as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: performing deep eutectic solvent extraction and purification on codonopsis pilosula, scalded rhizoma drynariae, herba epimedii and eucommia ulmoides to prepare a traditional Chinese medicine extract, and performing water extraction, dialysis and drying on cornu cervi pantotrichum to prepare cornu cervi pantotrichum protein peptide; performing water extraction and alcohol precipitation on cistanche to prepare cistanche polysaccharide; hydroxyapatite is modified by citric acid, sodium dihydrogen phosphate and beta-cyclodextrin, calcium salt, alpha-calciferol and vitamin D3 are included, the prepared product is uniformly mixed with a traditional Chinese medicine extract, cornu cervi pantotrichum protein peptide and cistanche polysaccharide, and the traditional Chinese medicine granules for improving osteoporosis are prepared. The prepared traditional Chinese medicine granules for improving osteoporosis can promote synthesis of collagen and bone matrix protein, inhibit bone resorption, promote bone remodeling and enhance the activity of osteoblasts, have a very good improvement effect on symptoms such as osteoporosis and fracture, and have a wide application prospect.

The invention discloses application of Plitidepsin in preparation of a medicine for treating osteoporosis caused by estrogen deficiency, and belongs to the field of biological medicine. The cyclic oligopeptide activates an Nrf2 / HO-1 antioxidant pathway and inhibits NF-kappa B and MAPK pathways by reducing the active oxygen level in osteoclasts, thereby inhibiting osteoclast differentiation, maturation and bone resorption activity. Experiments prove that 10-40 [mu] g / kg of Plitidepsin can be applied in a subcutaneous injection manner, and can down-regulate the specific gene expression of osteoclasts and reduce bone loss.